肝巨噬细胞极化对肝硬化发生的影响及临床应用研究进展*

doi:10.3969/j.issn.1672-5069.2023.01.039

Abstract

Wu Di, Luo Yehao, Huang An. Impact of hepatic macrophages polarization on pathogenesis of liver cirrhosis[J]. Journal of Practical Hepatology, 2023, 26(1): 149-152.

[1] GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet,2020,5(3):245-266.
[2] Asrani SK, Devarbhavi H, Eaton J, et al. Burden of liver diseases in the world. J Hepatol, 2019,70(1):151-171.
[3] Palmer LB, Kuftinec G, Pearlman M, et al. Nutrition in cirrhosis.Curr Gastroenterol Rep, 2019,21(8):38.
[4] Locati M, Curtale G, Mantovani A. Diversity, mechanisms, and significance of macrophage plasticity. Annu Rev Pathol, 2020,15:123-147.
[5] Van der Heide D, Weiskirchen R, Bansal R. Therapeutic targeting of hepatic macrophages for the treatment of liver diseases. Front Immunol, 2019,10:2852.
[6] Shan Z, Ju C. Hepatic macrophages in liver injury. Front Immunol,2020,11:322.
[7] Uderhardt S, Martins AJ, Tsang JS, et al. Resident macrophages cloak tissue microlesions to prevent neutrophil-driven inflammatory damage. Cell,2019,177(3):541-555,e617.
[8] Horst AK, Tiegs G, Diehl L. Contribution of macrophage efferocytosis to liver homeostasis and disease. Front Immunol,2019,10:2670.
[9] Elchaninov AV, Fatkhudinov TK, Vishnyakova PA, et al. Phenotypical and functional polymorphism of liver resident macrophages. Cells,2019,8(9):1032.
[10] Wen Y, Lambrecht J, Ju C, et al. Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities. Cell Mol Immunol, 2021,18(1):45-56.
[11] Muntjewerff EM, Meesters LD, van den Bogaart G. Antigen cross-presentation by macrophages. Front Immunol,2020,11:1276.
[12] Dou L, Shi X, He X, et al. Macrophage phenotype and function in liver disorder. Front Immunol,2020,10:3112.
[13] Geervliet E, Bansal R. Matrix metalloproteinases as potential biomarkers and therapeutic targets in liver diseases. Cells,2020,9(5):1212.
[14] Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol,2021,18(3):151-166.
[15] Gao B, Ahmad MF, Nagy LE, et al. Inflammatory pathways in alcoholic steatohepatitis. J Hepatol,2019,70(2):249-259.
[16] Kany S, Vollrath JT, Relja B. Cytokines in inflammatory disease. Int J Mol Sci,2019,20(23):6008.
[17] Zhou R, Fan X, Schnabl B. Role of the intestinal microbiome in liver fibrosis development and new treatment strategies. Transl Res,2019,209:22-38.
[18] Fukui H. Leaky gut and gut-liver axis in liver cirrhosis: clinical studies update. Gut Liver,2021,15(5):666-676.
[19] Meyer F, Bannert K, Wiese M, et al. Molecular mechanism contributing to malnutrition and sarcopenia in patients with liver cirrhosis. Int J Mol Sci,2020,21(15):5357.
[20] Shrivastava R, Shukla N. Attributes of alternatively activated (M2) macrophages. Life Sci,2019,224:222-231.
[21] Luque-Campos N, Bustamante-Barrientos FA, Pradenas C, et al. The macrophage response is driven by mesenchymal stem cell-mediated metabolic reprogramming. Front Immunol,2021,12:624746.
[22] Gan J, Liu C, Li H, et al. Accelerated wound healing in diabetes by reprogramming the macrophages with particle-induced clustering of the mannose receptors. Biomaterials,2019,219:119340.
[23] Wang LX, Zhang SX, Wu HJ, et al. M2b macrophage polarization and its roles in diseases. J Leukoc Biol,2019,106(2):345-358.
[24] Ye L, He S, Mao X,et al. Effect of hepatic macrophage polarization and apoptosis on liver ischemia and reperfusion injury during liver transplantation. Front Immunol,2020,11:1193.
[25] Orecchioni M, Ghosheh Y, Pramod AB, et al. Macrophage polarization: different gene signatures in M1(LPS⁺) vs. classically and M2(LPS^-) vs. alternatively activated macrophages. Front Immunol, 2019,10:1084.
[26] Cheng D, Chai J, Wang H, et al. Hepatic macrophages: key players in the development and progression of liver fibrosis. Liver Int,2021,41(10):2279-2294.
[27] Sumitomo R, Hirai T, Fujita M, et al. M2 tumor-associated macrophages promote tumor progression in non-small-cell lung cancer. Exp Ther Med, 2019,18(6):4490-4498.
[28] Yahaya MAF, Lila MAM, Ismail S, et al. Tumour-associated macrophages (TAMs) in colon cancer and how to reeducate them. J Immunol Res,2019,2019:2368249.
[29] Cao L, Che X, Qiu X, et al. M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer. Cancer Manag Res,2019,11:6125-6138.
[30] Colino CI, Lanao JM, Gutierrez-Millan C. Targeting of hepatic macrophages by therapeutic nanoparticles. Front Immunol,2020,11:218.
[31] Lee CH, Chun T. Anti-inflammatory role of TAM family of receptor tyrosine kinases via modulating macrophage function. Mol Cells,2019,42(1):1-7.
[32] Chang Y, Li H. Hepatic antifibrotic pharmacotherapy: as we approaching success? J Clin Transl Hepatol,2020,8(2):222-229.
[33] Wu BM, Liu JD, Li YH, et al. Margatoxin mitigates CCl₄induced hepatic fibrosis in mice via macrophage polarization, cytokine secretion and STAT signaling. Int J Mol Med,2020,45(1):103-114.
[34] Ahn SB, Jun DW, Kang BK, et al. Randomized, double-blind, placebo-controlled study of a multispecies probiotic mixture in nonalcoholic fatty liver disease. Sci Rep,2019,9(1):5688.
[35] Lee NY, Suk KT. The role of the gut microbiome in liver cirrhosis treatment. Int J Mol Sci,2020,22(1):199.
[36] Milosevic I, Vujovic A, Barac A, et al. Gut-liver axis, gut microbiota, and Its modulation in the management of liver diseases: a review of the literature. Int J Mol Sci,2019,20(2):395.
[37] Ambade A, Lowe P, Kodys K, et al. Pharmacological inhibition of CCR2/5 signaling prevents and reverses alcohol-induced liver damage, steatosis, and inflammation in mice. Hepatology,2019,69(3):1105-1121.
[38] Hintermann E, Christen U. The many roles of cell adhesion molecules in hepatic fibrosis. Cells,2019,8(12):1503.
[39] Piersma B, Bank RA. Collagen cross-linking mediated by lysyl hydroxylase 2: an enzymatic battlefield to combat fibrosis. Essays Biochem,2019,63(3):377-387.
[40] Zhou GP, Jiang YZ, Sun LY, et al. Therapeutic effect and safety of stem cell therapy for chronic liver disease: a systematic review and meta-analysis of randomized controlled trials. Stem Cell Res Ther, 2020,11(1):419.
[41] Kweon M, Kim JY, Jun JH, et al. Research trends in the efficacy of stem cell therapy for hepatic diseases based on microRNA profiling. Int J Mol Sci, 2020,22(1):239.
[42] Moon SH, Lee CM, Park SH, et al. Effects of hepatocyte growth factor gene-transfected mesenchymal stem cells on dimethylnitrosamine-induced liver fibrosis in rats. Growth Factors, 2019,37(3-4):105-119.

Impact of hepatic macrophages polarization on pathogenesis of liver cirrhosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Li Rui, Qin Qiushi, Zhang Yue, et al. Role of E series of prostaglandin receptor 4 on liver fibrosis-related protein expression in mice with carbon tetrachloride-induced liver injuries [J]. Journal of Practical Hepatology, 2023, 26(1): 15-18.
[2]	Wang Yan, Li Weijia, Li Ya, et al. Micro-122 levels in liver fibrosis in vitro and in vivo [J]. Journal of Practical Hepatology, 2023, 26(1): 19-22.
[3]	Xu Haibo, Su Huiting, Xiong Yiping, et al. Changes of peripheral blood dNLR, MLR and SII in patients with hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2023, 26(1): 71-74.
[4]	Li Susu, Dong Yuan, Jia Haoyan, et al. Observation of ornithine aspartate at base of colon dialysis in treatment of patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2023, 26(1): 75-78.
[5]	Chen Ye, Chen Xiaolan, Cao Liling, et al. Cardiac structural and functional changes in patients with hepatitis B cirrhosis after undergoing transjugular intrahepatic portosystemic shunt [J]. Journal of Practical Hepatology, 2023, 26(1): 79-82.
[6]	Liu Nannan, Li Wei, Zhao Shousong. Diagnostic performance of simplified animal nomenclature test in predicting minimal hepatic encephalopathy in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2023, 26(1): 83-86.
[7]	Dai Huan, Li Kai, Zhu Yongxiang, et al. Efficacy of endoscopic ligation and tissue glue injection in the treatment of patients with hepatitis B liver cirrhosis and esophageal and gastric varices bleeding [J]. Journal of Practical Hepatology, 2023, 26(1): 87-90.
[8]	Xu Qing, Yang Jian, Zong Jinjuan. Imaging and histopathological features in patients with idiopathic non-cirrhotic portal hypertension [J]. Journal of Practical Hepatology, 2023, 26(1): 91-94.
[9]	Jiang Yingying, Ding Huiguo. Current status and challenges of clinical management of cirrhotics with acute kidney injury [J]. Journal of Practical Hepatology, 2022, 25(6): 764-767.
[10]	Han Fang, Li Jiazheng, Nan Yuemin. Management of acute kidney injury in patients with livercirrhosis [J]. Journal of Practical Hepatology, 2022, 25(6): 768-771.
[11]	Wang Xiaohua, Zeng Yalin, Guo Cuirong. Impact of impaired fasting glucose and insulin resistance on liver fibrosis in patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(6): 812-815.
[12]	Shen Yiliang, Shen Dongyuan, Chen Yongying, et al.. Qualitative evaluation of intrahepatic nodules in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(6): 836-839.
[13]	Lin Xiuhui, Li Nan, Zhang Jiaozhen, et al.. Polymorphisms of PNPLA3 and PRKAA1 genes and their correlation to liver cirrhosis in patients with hepatitis B viral infection [J]. Journal of Practical Hepatology, 2022, 25(6): 844-847.
[14]	Zhu Haiyan, Fan Xiaotang. Nomogram model in predicting portal venous thrombosis in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(6): 848-852.
[15]	Sun Jing, Zhang Weiwei, Ma Zhiyong, et al.. Prevention of varices re-bleeding in patients with liver cirrhosis undergoing transjugular intrahepatic portosystemie stent and gastric coronary vein embolization [J]. Journal of Practical Hepatology, 2022, 25(6): 853-856.